Lilly has announced plans to invest $5 billion to establish a new manufacturing facility west of Richmond, Virginia. The site will be the company’s first dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for its bioconjugate platform
GSK announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years. The investment includes a new $1.2 billion commitment to advanced manufacturing facilities and AI and advanced
Life sciences supply chains are moving out of China. This trend briefing, powered by SmartCube, summarises the key points you need to know.
Vertex Pharmaceuticals and Lonza have recently announced a strategic collaboration aimed at supporting the manufacturing of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with Type 1 Diabetes. The 130,000ft² site will be run
Fuliginous Management Consulting regularly tracks the outsourcing activity of 320 pharma companies operating in Europe. In this new research, Kyriakos Kansos reveals some of the key trends in external manufacturing and advises how companies can optimise their pharmaceutical manufacturing network.
The Pharmaceutical Supply Chain Risk Assessment Act is the latest legislation introduced in the US senate to reduce the United States’ dependence on importing drugs from foreign countries. The legislation will have government agencies investigate supply chain weaknesses, siting the
French President Emmanuel Macron has announced plans to bring pharmaceutical production back to France. In a recent speech, he stated that the COVID-19 pandemic has highlighted the need for France to be more self-sufficient in terms of medical supplies. “We
AstraZeneca has recently announced a partnership with Vanguard Renewables to supply renewable natural gas (RNG) to its U.S. manufacturing facilities. This move is part of AstraZeneca’s commitment to reducing its environmental impact by using organic-produced fuel in all of its
Novo Nordisk, the Danish pharmaceutical company, recently announced its plans to invest 15.9 billion Danish kroner (around $2.3 billion) in expanding its manufacturing capacity for chronic disease medications at a facility located north of Copenhagen . This investment follows previous
Samsung Biologics has entered into a strategic partnership for the long-term commercial manufacturing of Pfizer’s multi-product biosimilars portfolio. Under the new deal, valued at $411 Million, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
